Diabetes: novel therapeutic developments. 21-22 September 1999, London, UK.
The treatment of diabetes represents an extremely active area of new product development. The goal is to effectively regulate glucose in a physiological manner, so as to reduce HbA1c levels and the complications of diabetes. An extremely broad range of new products for the treatment of Type I and/or Type II diabetes are in the pipeline. These include: new forms and methods of delivering insulin to increase compliance; novel pharmaceutical agents to reduce serum glucose and HbA1c levels; immunoregulatory agents which will prevent or reverse diabetic autoimmunity; glucose sensor-insulin pump feedback loops; and, transplantation of xenogeneic islets in immunoprotected microreactors.
Wolf
D E
DE
BioHybrid Technologies Inc, Park Nine West, Shrewsbury, MA 01545, USA. stiwolf@aol.com